ToxoTech, a biopharmaceutical company pioneering enhanced botulinum neurotoxin therapies, today announced an investment from Swedish venture capital fund Industrifonden. The funding will accelerate the development of ToxoTech’s novel botulinum platform, designed to provide patients with longer-lasting therapeutic benefits compared to current treatments.
Botulinum neurotoxins have been used for decades to treat a wide range of neuromuscular and neurological disorders – from spasticity following stroke, to movement disorders such as cervical dystonia, to chronic migraine. While safe and effective, today’s therapies require patients to return for treatment everythree to four months, placing a significant burden on both patients and healthcare systems.
- Our vision is to deliver a new generation of botulinum neurotoxin therapies that combine precision with durability. With Industrifonden’s support, we are well positioned to bring forward therapies that can significantly reduce the treatment burden and improve outcomes for patients living with neurological disorders, said Geoffrey Masuyer, PhD, CEO and co-founder of ToxoTech.
ToxoTech has developed a technology based on an engineered botulinum neurotoxin with improved targeting and durability. ToxoTech’s innovation has the potential to transform care by reducing the frequency of injections and hospital visits needed, thereby improving patient quality of life and optimizing healthcare resources.
- We are excited to back ToxoTech in their mission to transform neurological care.Their deep scientific expertise, coupled with a clear path to meaningful patient impact, aligns closely with our focus on supporting pioneering life science companies, said Jonathan Ilicki, Investment Manager at Industrifonden.
